A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

WHO includes ArkBio' paediatric RSV drug, ziresovir in PADO-RSV priority list: Shanghai, China Thursday, July 17, 2025, 14:00 Hrs [IST] Shanghai Ark Biopharmaceutical Co., Ltd. (A ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Ziresovir earns global recognition, boosting hope for young RSV patients and strengthening ArkBio’s innovative pipeline.

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

The treatment reduced the risk of hospitalization by 83% U.S. babies enjoyed better protection because treatment was prioritized for high-risk infants TUESDAY, May 6, 2025 (HealthDay News ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.